Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (HAE)
NYSE:HAE
Holding HAE?
Track your performance easily
HAE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$70.74 - $97.97
Previous Close$75.61
Volume589.68K
Average Volume (3M)592.49K
Market Cap
$3.87B
Enterprise Value$4.75B
Total Cash (Recent Filing)$344.43M
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)33.9
Beta0.79
Next Earnings
Nov 05, 2024EPS Estimate
$1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.23
Shares Outstanding51,177,734
10 Day Avg. Volume620,936
30 Day Avg. Volume592,487
Standard Deviation0.11
R-Squared0.02
Alpha-0.00627
Financial Highlights & Ratios
Price to Book (P/B)4.27
Price to Sales (P/S)2.94
Price to Cash Flow (P/CF)-35.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.56
Enterprise Value/Gross Profit6.87
Enterprise Value/Ebitda18.20
Forecast
1Y Price Target
$106.14Price Target Upside41.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Haemonetics News
Bulls Say, Bears Say
Bulls Say
Hospital Segment GrowthHAE is a major player in the plasma collection technology market, and the Hospital segment is expected to grow significantly and become the largest contributor to total sales.
Market GrowthThe medical device maker primarily focused on plasma collection and vascular closure should benefit from strong underlying market growth trends which should ultimately help to expand margins.
Product LaunchGoing forward, HAE to benefit from the recent launch of the larger VASCADE MVP XL which should give the company more exposure to the pulse field ablation and left atrial appendage closure (LAAC) markets, both growing 20+%.
Bears Say
Business PerformanceThe plasma business declined 2.7% on a reported basis and decreased 2.6% organically.
Financial PerformanceHAE's operating margin was down by 150 bps Y/Y.
Investor ConfidenceHAE shares are down ~15% since fiscal Q1 results in early August as investors’ confidence in Street numbers was shaken.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
HAE FAQ
What was Haemonetics Corp.’s price range in the past 12 months?
Haemonetics Corp. lowest stock price was $70.74 and its highest was $97.97 in the past 12 months.
What is Haemonetics Corp.’s market cap?
Currently, no data Available
When is Haemonetics Corp.’s upcoming earnings report date?
Haemonetics Corp.’s upcoming earnings report date is Nov 05, 2024 which is in 46 days.
How were Haemonetics Corp.’s earnings last quarter?
Haemonetics Corp. released its earnings results on Aug 08, 2024. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $1.005 by $0.015.
Is Haemonetics Corp. overvalued?
According to Wall Street analysts Haemonetics Corp.’s price is currently Undervalued.
Does Haemonetics Corp. pay dividends?
Haemonetics Corp. does not currently pay dividends.
What is Haemonetics Corp.’s EPS estimate?
Haemonetics Corp.’s EPS estimate is $1.08.
How many shares outstanding does Haemonetics Corp. have?
Haemonetics Corp. has 51,177,734 shares outstanding.
What happened to Haemonetics Corp.’s price movement after its last earnings report?
Haemonetics Corp. reported an EPS of $1.02 in its last earnings report, beating expectations of $1.005. Following the earnings report the stock price went down -10.838%.
Which hedge fund is a major shareholder of Haemonetics Corp.?
Among the largest hedge funds holding Haemonetics Corp.’s share is Royce & Associates LLC. It holds Haemonetics Corp.’s shares valued at 98M.
---
Haemonetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$106.14 (41.37% Upside)
$106.14 (41.37% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 106.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 17.4%
Last 30 Days ▼ 17.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.04%
12-Months-Change
Fundamentals
Return on Equity
12.98%
Trailing 12-Months
Asset Growth
29.49%
Trailing 12-Months
Company Description
Haemonetics Corp.
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.
---
HAE Earnings Call
Q1 2024
0:00 / 0:00
---
HAE Stock 12 Month Forecast
Average Price Target
$106.14
▲(41.37% Upside)
Technical Analysis
Best Analysts Covering HAE
1 Year
1 Year Success Rate
27/46 ratings generated profit
1 Year Average Return
+8.36%
reiterated a buy rating 4 months ago
Copying Anthony Petrone's trades and holding each position for 1 Year would result in 58.70% of your transactions generating a profit, with an average return of +8.36% per trade.
---